Serum CA 19-9 of Pancreatic Solid Mass Patients in Dr. Cipto Mangunkusumo National Central General Hospital

Authors

  • Kaka Renaldi Division of Gastroenterology, Department of Internal Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta
  • Adelia Nova Prahasary Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Muhammad Hamdan Yuwaafi Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Muhammad Maulana Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta

DOI:

https://doi.org/10.24871/2132020188-192

Keywords:

CA-19 9, adenocarcinoma pancreas, bilirubin, resectability

Abstract

Background: Pancreatic cancer is a lethal disease associated with poor prognosis. CA 19-9 is one of the elevated tumor markers in pancreatic cancer. However, data regarding CA 19-9 serum levels in pancreatic cancer in Indonesia is still scarce. This study aims to evaluate the clinical use of CA 19-9 in pancreatic cancer patients in Dr. Cipto Mangunkusumo National Central General Hospital.

Method: This study is a cross-sectional study that served data of demographic information, CA 19-9 level, TNM stage, site, histopathology, and resectability of pancreatic cancer. This study included 77 subjects. The data were collected from electronic medical records and registered data of patients in the Gastrointestinal Endoscopy Center, Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta between 2014 to 2019. Sensitivity and specificity analysis of CA 19-9 were performed using the ROC curve.

Results: We found 77 pancreatic cancer patients with a mean age of 54.2+10.4 years old. Most of them were males (59,7%), were found at stadium IV (41,6%) and unresectable tumor (68,8%). Non-adenocarcinoma which was mainly found in the head of the pancreas (76,6%) were confirmed in 67,5% of patients. The sensitivity and specificity of CA-19 9 to diagnose adenocarcinoma pancreas were 32% and 62% (p=0.939).

Conclusion: CA 19-9 should be used in aiding diagnosis, in conjunction with other modalities, such as radiological procedures and histopathology results. Measuring serum CA19-9 level in the early diagnosis could guide clinicians in determining the treatment and prognosis of pancreatic cancer.

Downloads

Published

2020-12-30

How to Cite

Renaldi, K., Prahasary, A. N., Yuwaafi, M. H., & Maulana, M. (2020). Serum CA 19-9 of Pancreatic Solid Mass Patients in Dr. Cipto Mangunkusumo National Central General Hospital. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 21(3), 188–192. https://doi.org/10.24871/2132020188-192

Issue

Vol. 21 No. 3 (2020): VOLUME 21, NUMBER 3, December 2020

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).